<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003867</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067031</org_study_id>
    <secondary_id>P30CA013330</secondary_id>
    <secondary_id>AECM-1199903068</secondary_id>
    <secondary_id>NCI-V99-1541</secondary_id>
    <nct_id>NCT00003867</nct_id>
  </id_info>
  <brief_title>Irinotecan and Capecitabine in Treating Patients With Solid Tumors</brief_title>
  <official_title>Phase I Clinical Study of Every Three Week Irinotecan With Oral Capecitabine Given Twice Daily for Two Weeks Out of Three in Patients With Gastrointestinal and Other Solid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Montefiore Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Montefiore Medical Center</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase I trial to study the effectiveness of irinotecan and capecitabine in treating
      patients who have solid tumors that have not responded to previous treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the maximum tolerated dose and toxic effects of irinotecan and oral
      capecitabine in patients with gastrointestinal or other solid tumors. II. Characterize the
      relationship at the recommended phase II dose between thymidine synthase and thymidine
      phosphorylase expression and tumor response and/or toxic effects in these patients.

      OUTLINE: This is a dose escalation study. Patients receive oral capecitabine twice daily
      every twelve hours for 14 days, and IV irinotecan over 30 minutes once every 3 weeks
      beginning on day 1. Treatment continues for at least 2 courses in the absence of disease
      progression or unacceptable toxicity. The dose of capecitabine and irinotecan is escalated in
      cohorts of 3-6 patients until the maximum tolerated dose (MTD) is determined. The MTD is
      defined as the dose at which 2 of 6 patients experience dose limiting toxicity.

      PROJECTED ACCRUAL: Approximately 25-30 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1999</start_date>
  <completion_date type="Actual">March 2003</completion_date>
  <primary_completion_date type="Actual">March 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Actual">30</enrollment>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>irinotecan hydrochloride</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically confirmed solid tumors, including but not limited
        to breast, gastrointestinal, and unknown primary cancer that is refractory to standard
        therapy or for which no standard therapy exists No known bone marrow involvement

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60-100% Life
        expectancy: Not specified Hematopoietic: Absolute neutrophil count at least 1,500/mm3 OR
        WBC at least 3,500/mm3 AND Platelet count at least 100,000/mm3 Hepatic: Bilirubin no
        greater than 1.5 mg/dL No known Gilbert's syndrome No other significant hepatic disease
        requiring medication Renal: Creatinine no greater than 1.5 mg/dL Cardiovascular: No
        significant cardiac disease requiring medication Other: Not pregnant or nursing Fertile
        patients must use effective contraception No other significant medical condition

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 2 weeks since prior colony stimulating
        factor and other cytokines active on bone marrow Chemotherapy: At least 4 weeks since prior
        chemotherapy (6 weeks since mitomycin or nitrosoureas) No prior or concurrent irinotecan
        and fluorouracil therapy Endocrine therapy: Not specified Radiotherapy: At least 4 weeks
        since prior radiotherapy No concurrent radiotherapy Surgery: Recovered from prior major
        surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sridhar Mani, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Albert Einstein College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Albert Einstein Comprehensive Cancer Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Goel S, Jhawer M, Rajdev L, Hopkins U, Fehn K, Baker C, Chun HG, Makower D, Landau L, Hoffman A, Wadler S, Mani S. Phase I clinical trial of irinotecan with oral capecitabine in patients with gastrointestinal and other solid malignancies. Am J Clin Oncol. 2002 Oct;25(5):528-34.</citation>
    <PMID>12393999</PMID>
  </results_reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>February 13, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2004</study_first_posted>
  <last_update_submitted>September 6, 2018</last_update_submitted>
  <last_update_submitted_qc>September 6, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III colon cancer</keyword>
  <keyword>stage IV colon cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage III gastric cancer</keyword>
  <keyword>stage IV gastric cancer</keyword>
  <keyword>recurrent gastric cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage II pancreatic cancer</keyword>
  <keyword>stage III pancreatic cancer</keyword>
  <keyword>recurrent pancreatic cancer</keyword>
  <keyword>stage III rectal cancer</keyword>
  <keyword>stage IV rectal cancer</keyword>
  <keyword>recurrent colon cancer</keyword>
  <keyword>recurrent rectal cancer</keyword>
  <keyword>stage IV anal cancer</keyword>
  <keyword>recurrent anal cancer</keyword>
  <keyword>stage II esophageal cancer</keyword>
  <keyword>stage III esophageal cancer</keyword>
  <keyword>stage IV esophageal cancer</keyword>
  <keyword>stage IIIA anal cancer</keyword>
  <keyword>stage IIIB anal cancer</keyword>
  <keyword>recurrent esophageal cancer</keyword>
  <keyword>regional gastrointestinal carcinoid tumor</keyword>
  <keyword>metastatic gastrointestinal carcinoid tumor</keyword>
  <keyword>recurrent gastrointestinal carcinoid tumor</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>recurrent adult primary liver cancer</keyword>
  <keyword>small intestine adenocarcinoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>small intestine leiomyosarcoma</keyword>
  <keyword>unresectable gallbladder cancer</keyword>
  <keyword>recurrent gallbladder cancer</keyword>
  <keyword>unresectable extrahepatic bile duct cancer</keyword>
  <keyword>recurrent extrahepatic bile duct cancer</keyword>
  <keyword>recurrent small intestine cancer</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>newly diagnosed carcinoma of unknown primary</keyword>
  <keyword>carcinoma of the appendix</keyword>
  <keyword>recurrent carcinoma of unknown primary</keyword>
  <keyword>stage IV pancreatic cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

